Freya Biosciences

Focus: Freya Biosciences is a Danish biotechnology company focused on microbial immunotherapies for women's health, specifically targeting vaginal dysbiosis and related conditions. The company operates as a pre-revenue biotech with a narrow therapeutic focus on underserved women's health indications.

Women's Health

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Freya Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Freya Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

IVF

Vaginal Flora Imbalance

N/A

Clinical Trials (1)

NCT05150639Vaginal Microbiome and IVF Pregnancy Outcome

N/A

Help build intelligence for Freya Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on an underserved therapeutic area (women's health microbial immunotherapies) with significant unmet medical need
Small, focused team structure enables direct impact on early-stage drug development programs
Novel modality (microbial immunotherapies) offers technical differentiation and learning in emerging field

Watch Out For

Pre-revenue stage with unknown funding runway creates financial stability uncertainty
Currently zero open positions indicates either early hiring freeze or minimal headcount
Early-stage pipeline with only Phase 2 programs and no Phase 3 data limits near-term value creation catalysts

Generated by Claude from Freya Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

FB101

Vaginal Flora Imbalance

N/A

Clinical Trials (1)

NCT05114031FB101 Intervention in Women Screened to Have Vaginal Dysbiosis

N/A

FB101

Vaginal Flora Imbalance

N/A

Clinical Trials (1)

NCT05850078FB101 Intervention in Women Screened to Have Vaginal Dysbiosis (Dyscover-3)

N/A